Cargando…

TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment

Chronic myeloid leukemia (CML) cells circulate between blood and bone marrow niche, representing different microenvironments. We studied the role of the two RNA-binding proteins, T-cell-restricted intracellular antigen (TIAR), and the fragile X mental retardation protein (FMRP) in the regulation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolczyk, Magdalena, Serwa, Remigiusz, Kominek, Agata, Klejman, Agata, Milek, Jacek, Chwałek, Marta, Turos-Korgul, Laura, Charzyńska, Agata, Dabrowski, Michal, Dziembowska, Magdalena, Skorski, Tomasz, Piwocka, Katarzyna, Podszywalow-Bartnicka, Paulina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140000/
https://www.ncbi.nlm.nih.gov/pubmed/37123244
http://dx.doi.org/10.1016/j.isci.2023.106543
Descripción
Sumario:Chronic myeloid leukemia (CML) cells circulate between blood and bone marrow niche, representing different microenvironments. We studied the role of the two RNA-binding proteins, T-cell-restricted intracellular antigen (TIAR), and the fragile X mental retardation protein (FMRP) in the regulation of protein translation in CML cells residing in settings mimicking peripheral blood microenvironment (PBM) and bone marrow microenvironment (BMM). The outcomes showed how conditions shaped the translation process through TIAR and FMRP activity, considering its relevance in therapy resistance. The QuaNCAT mass-spectrometric approach revealed that TIAR and FMRP have a discrete modulatory effect on protein synthesis and thus affect distinct aspects of leukemic cells functioning in the hypoxic niche. In the BMM setup, FMRP impacted metabolic adaptation of cells and TIAR substantially supported the resistance of CML cells to translation inhibition by homoharringtonine. Overall, our results demonstrated that targeting post-transcriptional control should be considered when designing anti-leukemia therapeutic solutions.